The 16 most recent market catalysts affecting $ALVO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 85
Alvotech shares are trading higher after the company announced FDA approval for a new manufacturing process for SIMLANDI.
The FDA approval for Alvotech's new manufacturing process for SIMLANDI (a Humira biosimilar) is a strong positive catalyst for the company. It suggests enhanced operational capabil…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Approves Alvotech’s Process 2.0 For SIMLANDI Drug Substance, More Than Doubling Output Per Batch Without Changing Upstream Manufacturing Scale
This FDA approval is a significant corporate catalyst for Alvotech, as it directly impacts their ability to produce SIMLANDI (a Humira biosimilar) more efficiently and cost-effecti…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech, Advanz Pharma File AVT29 Line Extension To Mynzepli Marketing Authorization With EMA For Proposed Eylea 8mg Biosimilar
The filing of a line extension for a proposed Eylea 8mg biosimilar by Alvotech and Advanz Pharma with the EMA is a significant corporate catalyst. This move directly threatens Rege…
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 65
Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products
Alvotech, a global biotechnology company, has partnered with LOTTE Biologics, a CDMO, for the long-term manufacturing of biosimilar drug substances. This agreement is significant f…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 85
Alvotech shares are trading higher after the company announced FDA approval for additional U.S. manufacturing capacity for SIMLANDI.
This FDA approval is a major positive catalyst for Alvotech, as it directly enables them to scale production of SIMLANDI, their biosimilar to Humira. Increased manufacturing capaci…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site
Alvotech announced that the FDA has approved its Reykjavik site to manufacture AVT02 (SIMLANDI) drug substance for U.S. commercial supply from either of its two suites, effectively…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech shares are trading higher after Barclays upgraded the stock from Underweight to Overweight rating and raised its price target from $4 to $8.
The upgrade from Underweight to Overweight by a major investment bank like Barclays, coupled with a doubling of the price target, is a significant positive catalyst for Alvotech. T…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8
Barclays analyst Glen Santangelo upgraded Alvotech (ALVO) from Underweight to Overweight and significantly raised the price target from $4 to $8. This move indicates a substantial …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech Announced That The U.S. Food And Drug Administration Has Accepted For Review A Biologics License Application For AVT80, A Proposed Interchangeable Biosimilar To Entyvio (Vedolizumab) Prefilled Syringe And Autoinjector For Subcutaneous Administration
This headline is a significant corporate catalyst for Alvotech, as the FDA's acceptance of the BLA for AVT80 brings them closer to commercializing a biosimilar to Entyvio. The 'int…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a $7 price target.
This headline represents a significant corporate catalyst for Alvotech. Analyst initiations, especially from major institutions like BofA Securities, often provide a strong endorse…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
B of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7
B of A Securities initiating coverage on Alvotech with a 'Buy' rating and a $7 price target is a positive development for the company. Analyst coverage, especially from a major ins…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets
This headline represents a significant positive catalyst for Alvotech (ALVO) as it secures a substantial upfront payment and future milestone payments, validating its biosimilar pi…
Aug 19, 2026
Corporate Catalyst
Bearish
Impact 95
Alvotech Q2 EPS $(0.17) Misses $(0.04) Estimate, Sales $106.000M Miss $111.010M Estimate
Alvotech's Q2 earnings per share of $(0.17) missed the consensus estimate of $(0.04) by a substantial 325%, and sales of $106 million missed the $111.01 million estimate by 4.51%. …
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 55
Evercore ISI Group Initiates Coverage On Alvotech with Outperform Rating
Evercore ISI Group, a well-known investment bank, has started covering Alvotech with an 'Outperform' rating. This is significant because new analyst coverage, especially with a pos…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Alvotech shares are trading higher. The company announced the FDA has closed its inspection of its Reykjavik manufacturing facility, classifying the site as Voluntary Action Indicated.
This headline represents a significant positive corporate catalyst for Alvotech. The FDA's VAI classification indicates that while some observations were made during the inspection…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
Alvotech Says FDA Closes Inspection Of Manufacturing Facility In Reykjavik, Iceland; FDA Confirms Inspection Classification Of Manufacturing Site Is Voluntary Action Indicated
Alvotech announced that the FDA has completed its inspection of their manufacturing facility in Reykjavik, Iceland, and classified the outcome as 'Voluntary Action Indicated' (VAI)…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.